Latest news with #AIMImmunoTech
Business Insider
7 hours ago
- Business
- Business Insider
AIM ImmunoTech receives noncompliance notification from NYSE
AIM ImmunoTech (AIM) announced the receipt of a warning notification from the NYSE stating that the company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide requiring stockholders' equity of $4M or more if the company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6M or more if the company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, the company had a stockholders' deficit of negative $3.9M and has had losses in the most recent five fiscal years ended December 31, 2024. Confident Investing Starts Here:
Yahoo
12 hours ago
- Business
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Cash, Cash Equivalents, and Marketable Securities: Approximately $4 million as of December 31, 2024. Research and Development Expenses: $6.2 million for the year ended December 31, 2024, compared to $10.9 million for the year ended December 31, 2023. General and Administrative Expenses: $13.7 million for the year ended December 31, 2024, compared to $21.1 million for the year ended December 31, 2023. Warning! GuruFocus has detected 6 Warning Signs with AIM. Release Date: April 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. AIM ImmunoTech Inc (AIM) announced a new clinical study evaluating Ampligen in combination with AstraZeneca's FluMist as a potential intranasal vaccine for influenza, including avian flu. The company strengthened its leadership team by adding two experienced Board members, Ted Kellner and David Chemerow, to guide strategic execution. The Erasmus Medical Center Safety Committee approved the continuation into the Phase 2 portion of the DURIPANC pancreatic cancer trial, marking progress in their clinical programs. AIM ImmunoTech Inc (AIM) reported final clinical results from the AMP-518 study, reinforcing Ampligen's potential in treating post-COVID conditions. The company expanded its intellectual property estate with new patents in the US and Netherlands, enhancing protection for Ampligen's applications. AIM ImmunoTech Inc (AIM) reported a decrease in cash, cash equivalents, and marketable securities to approximately $4 million as of December 31, 2024. Research and development expenses decreased from $10.9 million in 2023 to $6.2 million in 2024, indicating potential budget constraints. General and administrative expenses also decreased from $21.1 million in 2023 to $13.7 million in 2024, which may reflect cost-cutting measures. The company is facing challenges in maintaining its listing on the New York Stock Exchange American and is considering a reverse stock split to avoid delisting. Future clinical trials will require additional manufacturing of Ampligen, which necessitates capital investment and could pose a financial challenge. Q: Do you have adequate supply of Ampligen for all your clinical trials this year, and how easy would it be to get new supply? A: Thomas Equels, President, CEO, and Executive Vice Chairman, responded that they have a budget for Ampligen tied to ongoing clinical activities, ensuring sufficient supply for current trials. For future trials, manufacturing more Ampligen will require capital, but they are actively working with polymer manufacturers and other vendors to ensure a steady supply. They do not anticipate any supply issues unless unforeseen circumstances arise. Q: What are the financial highlights for AIM ImmunoTech for the year ended December 31, 2024? A: Thomas Equels noted that AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Research and development expenses were $6.2 million, down from $10.9 million in 2023. General and administrative expenses were $13.7 million, compared to $21.1 million in 2023. Q: What steps are being taken to maintain AIM ImmunoTech's listing on the New York Stock Exchange American? A: Thomas Equels emphasized that maintaining the listing is a major priority. They are evaluating all available options to maintain compliance, including a potential reverse stock split. A special meeting of stockholders will be held to authorize the Board to effect the reverse stock split to avoid delisting. Q: Can you provide an update on the DURIPANC pancreatic cancer trial? A: Thomas Equels stated that the Erasmus Medical Center Safety Committee has approved the continuation into the Phase 2 portion of the DURIPANC trial, which evaluates Ampligen in combination with AstraZeneca's Imfinzi. Dosing for Phase 2 has commenced, and they anticipate enrolling the final patient by the second or third quarter of 2026. Q: What are the upcoming milestones for AIM ImmunoTech's clinical programs? A: Thomas Equels highlighted several milestones, including the completion of a Phase 2 study in advanced ovarian cancer in the first half of 2025, the dosing of the first patient in a refractory melanoma study in the first half of 2025, and the completion of enrollment for a Stage 4 triple negative breast cancer trial by the second quarter of 2026. They are also planning a follow-up study for long COVID and a new clinical study evaluating Ampligen with FluMist for influenza. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
